CNMD · CONMED Corp
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Jul 29, 2026TL;DR. CONMED reported Q2 organic constant-currency sales growth of 6.0% and adjusted EPS of $1.38 (up 20%), aided by a $0.21 tariff-refund benefit, while raising full-year adjusted EPS guidance to $4.48–$4.60 but narrowing the top end of organic growth guidance to 5–6% from 5–6.5%.
- + Q2 adjusted EPS of $1.38, up 20% YoY, beating the high end of guidance (including a $0.21 tariff refund).
- + Raised full-year 2026 adjusted EPS guidance to $4.48–$4.60 from $4.30–$4.45.
- + Q2 organic constant-currency sales growth of 6.0% modestly exceeded the high end of expectations.
- − Narrowed top end of full-year organic constant-currency sales growth guidance to 5–6% from 5–6.5%, citing a more measured pace of H2 improvement.
- − Raised full-year adjusted interest expense assumption to ~$33M from prior $25M–$27M.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CNMD
this stock
CONMED Corp
|
$1.39B | +13.9% | +5.2% | — | 7.1% |
|
ABT
Abbott Laboratories
|
$174.90B | -21.1% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.2% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.2% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CNMD | +0.9% | -5.9% | +25.2% | -7.3% | +13.9% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +1.6% | -6.0% | +13.0% | -6.7% | +2.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.